HIV/AIDS Research
Anti-termination by SIV Tat requires flexibility of nascent TAR structure
Published in Blood Weekly, January 27th, 2005
"Substitution of the SIVmac239 promoter/enhancer by the strong EF1alpha promoter results in a severe replication defect due to a failure to respond to Tat. Revertant viruses with minimal promoter sequences (two Sp1 sites and a TATA box) were obtained that had fully restored their replicative 2 potential.
"Comparison of the different LTRs indicated that structural alterations in the TAR stem due to a 31 bp exon of the EF1alpha promoter rather than the mere presence of transcription factor binding sites within U3 were responsible for the attenuation," investigators in France...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-01-27)
More Articles from Blood Weekly
- Acute Lymphocytic Leukemia
Unrelated cord blood transplantation is an option for children with ALL - Adenovirus
Cidofovir effectively treats adenoviral hemorrhagic cystitis in HSCT patients - Embryonic Stem Cell Research
Cryopreservation technique increases ESC viability and reduces differentiation - Spinal Cord Injury
BMTs provide tissue protection/axon guidance after contusive spinal cord injury - Stem Cell Research
Trabecular bone fragment alternative source of mesenchymal stem cells - Acute Myelogenous Leukemia
Clinical outcome not affected in pediatric AML patients with PTPN11 mutations - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
